MESOBLAST Aktie

 

Mesoblast rises after completing treatment of 350 patients in a pivotal phase III study of rexlemestrocel-L for treating chronic low back pain....

Mesoblast faces big risks, but brokers see substantial upside if successful. The post Mesoblast shares are up sharply. Is this biotech still undervalued? appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Mesoblast (ASX:MSB) has completed patient treatment in its pivotal Phase 3 trial…...

It has been a good start to the week for this biotech company. The post Mesoblast share price jumps on blockbuster news appeared first on The Motley Fool Australia....

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth. The post Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB appeared first on The Motley Fool Australia....

Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases...

Does Mesoblast Limited (MESO) have what it takes to be a top stock pick for momentum investors? Let's find out....

Welcome to this week's HotCopper Highlights, where we look at the most…...

With more than 600k average monthly users on the HotCopper forums, each…...

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial....

This biotechnology company just became less risky according to Bell Potter. The post Why Mesoblast shares could double in value appeared first on The Motley Fool Australia....

Ryoncil® uptake has exceeded initial projections The post Mesoblast shares: Q4 earnings top projections appeared first on The Motley Fool Australia....

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received a Biologics License Application (BLA) filing number from the U.S. Food and Drug Administration (FDA) and has requested a modular review of its BLA for rexlemestrocel-L in prevention of life-threatening gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device (LVAD). Rexlemestrocel-L has received Orphan Drug Designation for prevention of life-threatening major mucosal bleeding events and has Regenerative Medicine Advanced Therapy (RMAT) designation for this patient population, providing eligibility for rolling and priority reviews of the BLA....

Optimized capital structure, retiring short-term maturing debt...

Issued on behalf of Conexeu Sciences Inc. Companies mentioned: Conexeu Sciences Inc. (NASDAQ: CNXU), Integra LifeSciences Holdings Corporation (NASDAQ: IART), Evolus, Inc. (NASDAQ: EOLS), Bioventus Inc. (NASDAQ: BVS), Mesoblast Limited (NASDAQ: MESO) KEY TAKEAWAYS A fresh Nasdaq debut.......

Analysts have given their verdict on these shares. Let's see what they are saying. The post Buy, hold, sell: Mesoblast, Mineral Resources, and Woolworths shares appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter. The post Mesoblast shares: Cash burn falls and Ryoncil® sales climb appeared first on The Motley Fool Australia....

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain...